Nephros (NEPH) Gets a Buy from Maxim Group
Maxim Group analyst Anthony Vendetti has reiterated a Buy rating on Nephros (NEPH), with shares closing at $4.60. The analyst consensus for Nephros is a Moderate Buy, with an average price target of $5.00. Vendetti specializes in the Healthcare sector, but has an average return of -23.2% and a 25.86% success rate on his stock recommendations.
In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Nephros. The company’s shares closed yesterday at $4.60.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, Lucid Diagnostics, and Daxor. According to TipRanks, Vendetti has an average return of -23.2% and a 25.86% success rate on recommended stocks.
Currently, the analyst consensus on Nephros is a Moderate Buy with an average price target of $5.00.
